Sanofi releases aide-mémoire for Q2 2026 results modeling
Pharmaceutical company Sanofi has released an aide-mémoire document to aid in the financial modeling of its Q2 2026 results.
Paris, France – July 1, 2026. Sanofi announced today the release of its aide-mémoire for the second quarter 2026 financial results. The document, available on the company's website within the Investors section, is designed to support analysts and investors in their financial modeling.
Prepared quarterly, the aide-mémoire provides detailed information on non-comparable items, foreign currency impact, and share count. This supporting document aims to offer a clearer understanding of the company's financial performance during the period. It serves as background information ahead of the full Q2 2026 earnings report, which is scheduled for publication on July 30, 2026.
Sanofi, a research and development-driven biopharmaceutical company, focuses on improving people's lives by developing medicines and vaccines. Leveraging its deep understanding of the immune system, the company creates innovative treatments with the potential to benefit millions worldwide. Sanofi maintains a pipeline of new therapeutic candidates under development.
The company will disclose its complete Q2 2026 financial results later this month. Today's announcement pertains solely to the technical document supporting financial analysis.